SEC Form 4 · accession 0001562180-18-002856
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer K. Moses
Officer — VP of Finance & Admin
Period of report
Jun 5, 2018
Accepted (ET)
Jun 5, 2018 · 2:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2018 | M | 750 | $0.39 | A | 750 | D | |
| Common Stock | Jun 5, 2018 | S | 750 | $38.77 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $0.39 | Jun 5, 2018 | M | 250 | D | — | Dec 5, 2023 | Common Stock | 250 | 0 | D |
| Stock Options (Right to Buy)F2 | $0.39 | Jun 5, 2018 | M | 500 | D | — | Jul 11, 2024 | Common Stock | 500 | 6,166 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2All shares underlying this option have vested.